|
Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls Clinical research trials and Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls. Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls  Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls
Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls
For Condition:
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Caffeine, the most widely used psychoactive drug in the world, exerts its behavioral effects by antagonizing adenosine receptors (AR). Four different human AR subtypes have been found and there is evidence that the stimulatory effect of caffeine is mainly caused by an inhibition of transmission via adenosine A(2a) receptors. A significant association has been found in healthy infrequent caffeine users between caffeine-induced anxiety and two linked polymorphisms on the A(2a) receptor gene, the 1976C greater than T and 2592C greater than Tins polymorphisms. In one study looking at monozygotic and dizygotic twin pairs, there was much evidence that individual differences in caffeine use, intoxication, tolerance, and withdrawal were substantially influenced by genetic factors. Family and twin studies have shown that genetic factors may increase vulnerability to panic disorder. In one study a systematic mutation screening and association study of the A(1) and A(2a) adenosine receptor genes in panic disorder showed a significant association between the 1976T allele and 1976T/T genotype of the A(2a) receptor gene and panic disorder. As the 1976T/T genotype of the A(2a) receptor gene has been associated with both increased caffeine-induced anxiety in healthy controls, and has been associated with increased vulnerability to panic disorder, we wish to study whether the 1976T/T genotype in panic disorder patients is associated with increased caffeine-induced anxiety. This study will study subjects with panic disorder and healthy controls. Based on previous studies the following hypotheses will be tested (2 replication and 2 new hypotheses): Replication; (1) panic disorder subjects will report higher anxiety after a caffeine challenge than the healthy control subjects. (2) healthy controls with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 C/T and 1976 C/C genotypes, New hypotheses; (3) panic patients (two separate groups: currently ill and remitted) with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to panic patients with the 1976 C/T and 1976 C/C genotypes, (4) panic patients (two separate groups: currently ill and remitted) with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 T/T genotype.
Details: Caffeine, the most widely used psychoactive drug in the world, exerts its behavioral effects by antagonizing adenosine receptors (AR). Four different human AR subtypes have been found and there is evidence that the stimulatory effect of caffeine is mainly caused by an inhibition of transmission via adenosine A(2a) receptors. A significant association has been found in healthy infrequent caffeine users between caffeine-induced anxiety and two linked polymorphisms on the A(2a) receptor gene, the 1976C greater than T and 2592C greater than Tins polymorphisms. In one study looking at monozygotic and dizygotic twin pairs, there was much evidence that individual differences in caffeine use, intoxication, tolerance, and withdrawal were substantially influenced by genetic factors. Family and twin studies have shown that genetic factors may increase vulnerability to panic disorder. In one study a systematic mutation screening and association study of the A(1) and A(2a) adenosine receptor genes in panic disorder showed a significant association between the 1976T allele and 1976T/T genotype of the A(2a) receptor gene and panic disorder. As the 1976T/T genotype of the A(2a) receptor gene has been associated with both increased caffeine-induced anxiety in healthy controls, and has been associated with increased vulnerability to panic disorder, we wish to study whether the 1976T/T genotype in panic disorder patients is associated with increased caffeine-induced anxiety. This study will study subjects with panic disorder and healthy controls. Based on previous studies the following hypotheses will be tested (2 replication and 2 new hypotheses): Replication; (1) panic disorder subjects will report higher anxiety after a caffeine challenge than the healthy control subjects. (2) healthy controls with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 C/T and 1976 C/C genotypes, New hypotheses; (3) panic patients (two separate groups: currently ill and remitted) with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to panic patients with the 1976 C/T and 1976 C/C genotypes, (4) panic patients (two separate groups: currently ill and remitted) with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 T/T polymorphism will report increased anxiety after a caffeine challenge compared to healthy controls with the 1976 T/T genotype.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: 1. Male or female subjects between ages 18 to 60. 2. Panic Disorder with a primary diagnosis of current Panic Disorder without Agoraphobia or Panic Disorder with Agoraphobia according to DSM-IV criteria. Patients with co-morbid Major Depressive Disorder will be included provided there has been a period of at least 3 months where Panic Disorder, currently in remission. Remission is defined by as not meeting criteria for Panic Disorder for at least 3 months and off treatment for at least 3 months immediately prior to study entry. 3. Subjects must be competent to comprehend the purpose of the study and provide written informed consent. 4. If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable method(s) of contraception (eg, hormonal intrauterine device), for at least one month prior to study entry and throughout the study. 5. Subjects must be psychotropic medication free for at lest 14 days prior to the caffeine/placebo challenge sessions. For fluoxetine at least 4 weeks. 6. Caffeine free diet for at least 7 days prior to the caffeine/placebo challenge sessions. EXCLUSION CRITERIA: 1. Subjects should have no general medical illness that is causing the panic disorder. 2. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease. 3. Subjects with know cardiac disease. 4. Subjects with one or more past seizures without a clear and resolved etiology. 5. Patients who would be unable to comply with study procedures or assessments. 6. Patients who are currently at high risk for homicide or suicide. 7. Patients with psychotic features. 8. Patients with current DSM-IV substance abuse or dependence within. 9. Patients who are on a non-psychotropic medication with psychotropic effects (e.g., beta-adrenergic blockers) unless the dosage has been stable for a minimum of one month prior to the study. 10. Subjects with a positive HIV test result. 11. Experimental treatment in the past one month. 12. For healthy volunteers, no current or past history of any psychiatric disorder. 13. Exclude subjects taking CYP1A2 inhibitors. 14. Exclude subjects with prostatitis.
Total Enrollment: 325
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 040183; 04-M-0183
Study Start Date: May 10, 2004
Record last reviewed: April 28, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083265
Related Studies:
Other Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Association Between Adenosine Receptor Gene Polymorphisms and Psychiological Responses to Caffeine in Subjects with Panic Disorder and Health Controls
|
|
|
|
|
|
|
|
